These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 18467844)

  • 1. Molecular analysis of the fragile histidine triad (FHIT) tumor suppressor gene in vesical tumors of cattle with chronic enzootic hematuria (CEH).
    Guidi E; Uboldi C; Ferretti L
    Cytogenet Genome Res; 2008; 120(1-2):173-7. PubMed ID: 18467844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative genomic mapping of the bovine Fragile Histidine Triad (FHIT) tumour suppressor gene: characterization of a 2 Mb BAC contig covering the locus, complete annotation of the gene, analysis of cDNA and of physiological expression profiles.
    Uboldi C; Guidi E; Roperto S; Russo V; Roperto F; Di Meo GP; Iannuzzi L; Floriot S; Boussaha M; Eggen A; Ferretti L
    BMC Genomics; 2006 May; 7():123. PubMed ID: 16719907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chromosome aberrations in cattle with chronic enzootic haematuria.
    Lioi MB; Barbieri R; Borzacchiello G; Dezzi S; Roperto S; Santoro A; Russo V; Roperto F
    J Comp Pathol; 2004; 131(2-3):233-6. PubMed ID: 15276863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of FRA16D/WWOX and FRA3B/FHIT genes in hematopoietic malignancies.
    Ishii H; Vecchione A; Furukawa Y; Sutheesophon K; Han SY; Druck T; Kuroki T; Trapasso F; Nishimura M; Saito Y; Ozawa K; Croce CM; Huebner K; Furukawa Y
    Mol Cancer Res; 2003 Nov; 1(13):940-7. PubMed ID: 14638866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Promoter methylation and loss of coding exons of the fragile histidine triad (FHIT) gene in intrahepatic cholangiocarcinomas.
    Foja S; Goldberg M; Schagdarsurengin U; Dammann R; Tannapfel A; Ballhausen WG
    Liver Int; 2005 Dec; 25(6):1202-8. PubMed ID: 16343073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer.
    Iliopoulos D; Guler G; Han SY; Johnston D; Druck T; McCorkell KA; Palazzo J; McCue PA; Baffa R; Huebner K
    Oncogene; 2005 Feb; 24(9):1625-33. PubMed ID: 15674328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequent silencing of fragile histidine triad gene (FHIT) in Burkitt's lymphoma is associated with aberrant hypermethylation.
    Hussain A; Gutiérrez MI; Timson G; Siraj AK; Deambrogi C; Al-Rasheed M; Gaidano G; Magrath I; Bhatia K
    Genes Chromosomes Cancer; 2004 Dec; 41(4):321-9. PubMed ID: 15384174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TP53 intronic mutations in bovine enzootic hematuria-associated urinary bladder tumors.
    Sasani F; Baghban F; Nikbakht Brujeni GH; Kazemi M
    Vet Pathol; 2013 May; 50(3):543-7. PubMed ID: 23242803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance.
    Nakata S; Sugio K; Uramoto H; Oyama T; Hanagiri T; Morita M; Yasumoto K
    Cancer; 2006 May; 106(10):2190-9. PubMed ID: 16598757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of fragile histidine triad gene expression in advanced lung cancer is consequent to allelic loss at 3p14 locus and promoter methylation.
    Wali A; Srinivasan R; Shabnam MS; Majumdar S; Joshi K; Behera D
    Mol Cancer Res; 2006 Feb; 4(2):93-9. PubMed ID: 16513840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequent deletions of FHIT and FRA3B in Barrett's metaplasia and esophageal adenocarcinomas.
    Michael D; Beer DG; Wilke CW; Miller DE; Glover TW
    Oncogene; 1997 Oct; 15(14):1653-9. PubMed ID: 9349498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of fragile histidine triad expression in tumors from saudi arabia: a tissue microarray analysis.
    Bavi P; Jehan Z; Atizado V; Al-Dossari H; Al-Dayel F; Tulbah A; Amr SS; Sheikh SS; Ezzat A; El-Solh H; Uddin S; Al-Kuraya K
    Cancer Epidemiol Biomarkers Prev; 2006 Sep; 15(9):1708-18. PubMed ID: 16985034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding the mechanisms of FHIT inactivation in cervical cancer for biomarker development.
    Lea JS; Ashfaq R; Muneer S; Burbee DG; Miller DS; Minna JD; Muller CY
    J Soc Gynecol Investig; 2004 Jul; 11(5):329-37. PubMed ID: 15219888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Semi-nested PCR for detection and typing of bovine Papillomavirus type 2 in urinary bladder and whole blood from cattle with enzootic haematuria.
    Wosiacki SR; Barreiro MA; Alfieri AF; Alfieri AA
    J Virol Methods; 2005 Jun; 126(1-2):215-9. PubMed ID: 15847940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Fragile Histidine Triad gene and breast cancer.
    Yang Q; Yoshimura G; Sakurai T; Kakudo K
    Med Sci Monit; 2002 Jul; 8(7):RA140-4. PubMed ID: 12118213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study of FHIT transcripts in normal and malignant breast tissue.
    Bièche I; Latil A; Becette V; Lidereau R
    Genes Chromosomes Cancer; 1998 Dec; 23(4):292-9. PubMed ID: 9824201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The FHIT gene at 3p14.2 is abnormal in breast carcinomas.
    Negrini M; Monaco C; Vorechovsky I; Ohta M; Druck T; Baffa R; Huebner K; Croce CM
    Cancer Res; 1996 Jul; 56(14):3173-9. PubMed ID: 8764101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of the common fragile site FRA3B does not affect FHIT expression.
    Michael D; Rajewsky MF
    Oncogene; 2001 Mar; 20(14):1798-801. PubMed ID: 11313927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two-hit inactivation of FHIT by loss of heterozygosity and hypermethylation in breast cancer.
    Yang Q; Nakamura M; Nakamura Y; Yoshimura G; Suzuma T; Umemura T; Shimizu Y; Mori I; Sakurai T; Kakudo K
    Clin Cancer Res; 2002 Sep; 8(9):2890-3. PubMed ID: 12231533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic silencing contributes to frequent loss of the fragile histidine triad tumour suppressor in basal cell carcinomas.
    Goldberg M; Rummelt C; Laerm A; Helmbold P; Holbach LM; Ballhausen WG
    Br J Dermatol; 2006 Dec; 155(6):1154-8. PubMed ID: 17107382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.